Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Launches PDReady™ Monoclonal Antibodies Kit

Published: Tuesday, December 11, 2012
Last Updated: Tuesday, December 11, 2012
Bookmark and Share
Integrates small-scale purification devices, process development protocols and technical support for rapid and efficient downstream process development.

Merck Millipore has launched its PDReady™ for Monoclonal Antibodies (MAbs) Kit for accelerating process development timelines.

The kit is based on a robust process development template using technologies for each purification operation.

Every step within the template uses a technology already proven to successfully purify MAbs, allowing biopharmaceutical manufacturers to rapidly develop a reliable purification process that delivers high purity and yield.

The PDReady™ for MAbs Kit reduces the complexity of process development by providing a single integrated package including purification devices, precise protocols to guide process development, specific recommendations for required laboratory tools, support from Merck Millipore technical experts, and equipment such as the Cogent® µScale that is loaned to the customer.

Each unit operation within the template is designed for convenient scaling from bench to clinic. By employing a proven template for MAb purification, the necessary experimentation for process development is drastically reduced, saving time, money and effort, while still developing a robust process.

"The PDReady™ for MAbs Kit leverages Merck Millipore's proven technologies to deliver a template for rapid and efficient downstream process development," said Vin Donovan, Vice President of Biopharm Process Solutions.

Donovan continued, "Our experience with these technologies in monoclonal antibody processes allows us to establish known process parameters, drastically reducing the experimentation required to achieve drug purity and yield targets. This speeds the time to clinic and ultimately commercial-scale production."

Purification unit operations within the PDReady™ for MAbs Kit include:
• Clarification - Millistak+® Pod Filter System
- Robust clarification in an easy-to-use format
• Affinity Chromatography - ProSep® Media
- Designed for cost-effective purification of high titer therapeutic antibodies
• Cation Exchange Chromatography - Fractogel® Media
- Provides reliability with optimal yields and efficient purification
• Anion Exchange Chromatography - ChromaSorb™ Membrane Absorber
- Provides the greatest levels of impurity binding at the highest salt concentrations for monoclonal antibodies
• Virus Filtration - Viresolve® Filters
- Robustly retains viruses while ensuring maximum product recovery
• Ultrafiltration - Pellicon® 3 Cassettes
- Tangential flow filtration device of choice for demanding filtration processes, including higher operating pressures, temperatures and caustic cleaning regimes
• Sterile Filtration (including buffers) - Millipore Express® Filters
- Provides sterility assurance, broad chemical compatibility, high flow rates and exceptionally high capacity
• Cogent® µScale TFF System
- Easy-to-use, semi-automated bench top TFF system for micro-scale process development and everyday low-volume ultrafiltration/diafilitration

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Announces Partnership with NIH Consortium
Adds more than 140 peer-validated neuroscience-specific monoclonal antibodies to portfolio.
Tuesday, October 16, 2012
Scientific News
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos